Add Yahoo as a preferred source to see more of our stories on Google. The U.S. Food and Drug Administration (FDA) has a black-box warning for Veozah, the first hormone-free medication for hot flashes.

Gloria Reuben is still using her voice to break stigmas-this time around menopause.

The FDA has issued a black-box warning for Veozah, a hot-flash medication, due to rare but serious liver risks Regular liver testing is recommended during Veozah treatment to ensure early detection of ...

Credit: Astellas The update follows the Food and Drug Administration’s review of a postmarketing case of serious liver injury. Hepatic function should be evaluated prior to initiating treatment with ...

Please provide your email address to receive an email when new articles are posted on . The FDA added a boxed warning to fezolinetant to highlight the known risk for rare but serious liver injury.

Top treatment choice: Hormone therapy remains the gold standard for hot flash relief, cutting frequency by 65–90%. Other available options: Non-hormonal drugs like SSRIs, gabapentin, and Veozah, plus ...

The FDA issued a warning regarding the potential risk of a rare but serious liver injury associated with the drug Veozah, a medication approved in May 2023 to treat moderate to severe hot flashes. The ...

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." “Women with bothersome hot flashes should not suffer in silence," says JoAnn V. Pinkerton, MD, professor ...

The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah, a medication used to relieve hot flashes in menopausal women, due to rare but ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...